When to Intervene in Renal Masses: Integrating Tumor Biology, Patient Fitness, and Competing Mortality Into Clinical Decision-Making

Renal cell carcinoma is among the most common urologic malignancies worldwide, with the majority of cases now detected incidentally at an early stage. Despite this shift toward earlier detection, clinical decision-making in the management of localized renal masses remains complex, particularly in elderly and comorbid patients. Existing guidelines provide a framework for management but fall short of offering a practical, risk-stratified algorithm for patients in whom competing comorbidities may outweigh the oncologic risk of the mass itself. This narrative review synthesizes current evidence on tumor biology, active surveillance (AS) outcomes, patient fitness assessment, intervention options, and competing mortality to address a central clinical question: when should we intervene in a renal mass, and when should we not? The evidence consistently supports the underuse of AS and the overuse of radical nephrectomy in elderly and high-comorbidity patients. A risk-stratified decision framework integrating tumor size, growth kinetics, frailty, and life expectancy is proposed to guide individualized management.